ZEISS Navigates Headwinds with Steady Results and a Bold Bet on Retinal Innovation

The optics giant posts solid half-year figures while doubling down on ophthalmology through a strategic investment in cutting-edge laser therapy technology.

ZEISS has reported a steady first half of its 2025/26 fiscal year, even as geopolitical turbulence and currency pressures weigh on its medical technology division. At the same time, the German optics powerhouse is signalling its long-term commitment to ophthalmology through a fresh venture investment in Maculaser, a Finnish medtech company developing a non-damaging retinal laser platform.

Mixed Picture Across the Group

The ZEISS Group posted revenue of €5.841 billion (approximately A$9.56 billion) for the six months ended 31 March 2026, up just one per cent on the prior corresponding period, while EBIT came in at €955 million (approximately A$1.56 billion). The headline numbers look respectable, but the detail tells a more complicated story.

The Medical Technology segment, encompassing ophthalmology and microsurgery, recorded revenue of €1.187 billion (approximately A$1.94 billion), down seven per cent in nominal terms. Meanwhile, the Semiconductor Manufacturing Technology segment grew six per cent to €2.612 billion (approximately A$4.28 billion), remaining the dominant earnings engine, a dependency CEO Andreas Pecher openly flagged as a structural concern alongside bloated cost structures inherited from years of strong growth.

In response, ZEISS is launching a competitiveness program targeting annual savings of several hundred million euros over the next three years, with job reductions expected. The foundation-owned company framed the move as deliberate rather than forced. R&D investment held firm at 14 per cent of revenue, or approximately €0.8 billion (approximately A$1.31 billion) for the half.

A New Frontier in Retinal Care

ZEISS Ventures has co-led a funding round in Maculaser alongside M2care, backing the Helsinki-based medtech company's push into clinical development for its patented, non-damaging, temperature-controlled retinal laser therapy. Born from Aalto University research, the technology targets AMD, diabetic maculopathy, and central serous chorioretinopathy, using real-time personalised temperature control of retinal tissue to activate the eye's natural cellular defence mechanisms and intervene before irreversible damage occurs.

For practitioners managing AMD and diabetic retinopathy caseloads, the proposition is clinically significant; a non-damaging, outpatient laser option deployable earlier in the disease course could meaningfully reduce reliance on anti-VEGF injections. ZEISS Ventures head Prof. Dr. Boris Hofmann said the technology could significantly delay or even prevent progression of retinal diseases, offering a safer and more effective option than current treatments.

With ZEISS not expecting market conditions to improve in the second half of the fiscal year, the group is clearly bracing for structural adjustment. But the Maculaser investment signals that ophthalmology innovation remains a strategic priority even as the business tightens its belt elsewhere.